Key Details
Price
$372.01Last Dividend
$1.63Annual Revenue
$171.34 BAnnual EPS
$25.22Annual ROE
15.81%Beta
0.39Events Calendar
Next earnings date:
Jan 24, 2025Recent quarterly earnings:
Oct 17, 2024Recent annual earnings:
Jan 24, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 05, 2024Next split:
N/ARecent split:
June 01, 2005Analyst ratings
Recent major analysts updates
Screeners with ELV included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Elevance Health is considered a good investment even after a 30% drop in its stock price, thanks to its strong fundamentals and position in the health insurance market. The company is well-placed to benefit from trends such as an aging population and longer life expectancy, which will increase the demand for healthcare services over time. However, there are some risks, including higher healthcare costs and a decrease in Medicaid members, which could affect profits and cash flow.
ELV is shifting its resources to focus on more profitable sectors and is making careful purchases.
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The law firm Robbins LLP, which focuses on shareholder rights, is looking into Elevance Health Inc. (NASDAQ: ELV) to find out if some of its officers and directors broke securities laws and failed to fulfill their responsibilities to shareholders. Elevance is a healthcare company that assists consumers, families, and communities throughout their care journey.
Anthem Blue Cross Blue Shield announced that it would stop covering anesthesia care if a surgery or procedure took longer than a set time limit. This decision led to criticism, and the parent company, Elevance Health Inc, decided to reverse the policy change.
SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The law firm Johnson Fistel, LLP is looking into whether Elevance Health, Inc. (NYSE: ELV) or its executives broke securities laws by not accurately sharing important information with investors. The investigation is centered on the losses suffered by investors and if these can be recovered under federal securities laws.
ELV is facing challenges like rising benefit costs, a higher level of debt, and losing members in its Medicaid sector, which worries investors.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The law firm Johnson Fistel, LLP is looking into whether Elevance Health, Inc. (NYSE: ELV) or its executives broke securities laws by not properly informing investors about important negative information. The investigation is centered on the losses suffered by investors and if they can be recovered under federal securities laws.
Elevance Health (NYSE: ELV) has just announced its Q3 results, showing that its revenue was higher than expected, but its earnings fell short of predictions. The company generated $44.7 billion in revenue and adjusted earnings of $8.37 per share, while analysts had estimated $43.5 billion in revenue and $9.66 in earnings.
On Thursday, Elevance Health Inc. (ELV) announced that its earnings for the third quarter were lower than anticipated.
Elevance Health's results for the third quarter of 2024 were not as good as expected, with a notable rise in the benefit expense ratio and reduced earnings forecasts for the year. I examine how much ELV relies on government plans and how profitable they are. Despite this, I believe Elevance stock is reasonably priced, even with cautious growth predictions for the near and long term.
FAQ
- What is the primary business of Elevance Health?
- What is the ticker symbol for Elevance Health?
- Does Elevance Health pay dividends?
- What sector is Elevance Health in?
- What industry is Elevance Health in?
- What country is Elevance Health based in?
- When did Elevance Health go public?
- Is Elevance Health in the S&P 500?
- Is Elevance Health in the NASDAQ 100?
- Is Elevance Health in the Dow Jones?
- When was Elevance Health's last earnings report?
- When does Elevance Health report earnings?
- Should I buy Elevance Health stock now?